Mainz Biomed Bv Stock Performance
| MYNZ Stock | USD 6.97 0.18 2.65% |
Mainz Biomed holds a performance score of 9 on a scale of zero to a hundred. The company secures a Beta (Market Risk) of -29.17, which conveys a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Mainz Biomed are expected to decrease by larger amounts. On the other hand, during market turmoil, Mainz Biomed is expected to outperform it. Use Mainz Biomed BV jensen alpha, potential upside, accumulation distribution, as well as the relationship between the treynor ratio and expected short fall , to analyze future returns on Mainz Biomed BV.
Risk-Adjusted Performance
9 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Mainz Biomed BV are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, Mainz Biomed showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 2.66 | Five Day Return (0.13) | Year To Date Return 495.79 | Ten Year Return (30.22) | All Time Return (30.22) |
Last Split Factor 1:40 | Last Split Date 2024-12-03 |
1 | Mainz Biomed stock plunges to 52-week low of 0.21 - Investing.com | 09/23/2024 |
2 | Mainz Biomed Publishes CEO Statement CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025 | 10/01/2024 |
3 | Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version | 10/08/2024 |
4 | Mainz Biomed B.V. GAAP EPS of -0.49, revenue of 520.77M | 10/21/2024 |
5 | Healthcare Giant Thermo Fisher Scientific Inc. Inks Deal With Mainz Biomed To Develop And Commercialize Next Gen Colorectal Cancer Screening | 11/12/2024 |
6 | Mainz Biomed Inks Major Deal To Develop A Next-Generation Cancer Test | 11/21/2024 |
7 | Mainz Biomed Announces Stock Split | 11/29/2024 |
8 | Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific | 12/03/2024 |
| Begin Period Cash Flow | 17.1 M | |
| Free Cash Flow | -23.8 M |
Mainz |
Mainz Biomed Relative Risk vs. Return Landscape
If you would invest 35.00 in Mainz Biomed BV on September 10, 2024 and sell it today you would earn a total of 662.00 from holding Mainz Biomed BV or generate 1891.43% return on investment over 90 days. Mainz Biomed BV is currently generating 15.1139% in daily expected returns and assumes 125.3627% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Mainz, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Mainz Biomed Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Mainz Biomed's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Mainz Biomed BV, and traders can use it to determine the average amount a Mainz Biomed's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1206
| Best Portfolio | Best Equity | MYNZ | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 125.36 actual daily | 96 96% of assets are less volatile |
Expected Return
| 5.01 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.12 actual daily | 9 91% of assets perform better |
Based on monthly moving average Mainz Biomed is performing at about 9% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Mainz Biomed by adding it to a well-diversified portfolio.
Mainz Biomed Fundamentals Growth
Mainz Stock prices reflect investors' perceptions of the future prospects and financial health of Mainz Biomed, and Mainz Biomed fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Mainz Stock performance.
| Return On Equity | -43.34 | ||||
| Return On Asset | -0.99 | ||||
| Operating Margin | (18.83) % | ||||
| Current Valuation | 21.25 M | ||||
| Shares Outstanding | 2 M | ||||
| Price To Book | 1.72 X | ||||
| Price To Sales | 15.22 X | ||||
| Revenue | 895.48 K | ||||
| Gross Profit | 177.62 K | ||||
| EBITDA | (25.01 M) | ||||
| Net Income | (26.3 M) | ||||
| Cash And Equivalents | 26.01 M | ||||
| Cash Per Share | 1.80 X | ||||
| Total Debt | 7.42 M | ||||
| Debt To Equity | 0.10 % | ||||
| Current Ratio | 10.83 X | ||||
| Book Value Per Share | (0.16) X | ||||
| Cash Flow From Operations | (21.94 M) | ||||
| Earnings Per Share | (44.40) X | ||||
| Market Capitalization | 13.96 M | ||||
| Total Asset | 15.41 M | ||||
| Retained Earnings | (69.33 M) | ||||
| Working Capital | (257.15 K) | ||||
About Mainz Biomed Performance
Evaluating Mainz Biomed's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Mainz Biomed has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Mainz Biomed has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 580.52 | 609.55 | |
| Return On Tangible Assets | (2.19) | (2.30) | |
| Return On Capital Employed | (4.32) | (4.10) | |
| Return On Assets | (1.71) | (1.79) | |
| Return On Equity | (8.09) | (7.69) |
Things to note about Mainz Biomed BV performance evaluation
Checking the ongoing alerts about Mainz Biomed for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Mainz Biomed BV help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Mainz Biomed BV is way too risky over 90 days horizon | |
| Mainz Biomed BV appears to be risky and price may revert if volatility continues | |
| Mainz Biomed BV has high likelihood to experience some financial distress in the next 2 years | |
| Mainz Biomed BVhas 3,566,004 shares shorted by Mainz Biomed investors is about 100% of outstending shares | |
| The company reported the previous year's revenue of 895.48 K. Net Loss for the year was (26.3 M) with profit before overhead, payroll, taxes, and interest of 177.62 K. | |
| Mainz Biomed BV currently holds about 26.01 M in cash with (21.94 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.8. | |
| Latest headline from benzinga.com: Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific |
- Analyzing Mainz Biomed's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Mainz Biomed's stock is overvalued or undervalued compared to its peers.
- Examining Mainz Biomed's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Mainz Biomed's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Mainz Biomed's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Mainz Biomed's stock. These opinions can provide insight into Mainz Biomed's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Mainz Stock Analysis
When running Mainz Biomed's price analysis, check to measure Mainz Biomed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mainz Biomed is operating at the current time. Most of Mainz Biomed's value examination focuses on studying past and present price action to predict the probability of Mainz Biomed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mainz Biomed's price. Additionally, you may evaluate how the addition of Mainz Biomed to your portfolios can decrease your overall portfolio volatility.